Equibles does not estimate personal net worth.
Get an email with a short summary when ClearPoint Neuro, Inc. publishes a filing, an earnings call transcript or a press release.
Get CLPT alertsDanilo D'Alessandro is recorded as CFO at ClearPoint Neuro, Inc. (CLPT). The proxy statement of ClearPoint Neuro, Inc. reports total compensation of $1,254,353 for Danilo D'Alessandro in fiscal 2025, including a base salary of $385,753. Disclosed compensation is on record for 6 fiscal years. Danilo D'Alessandro has spoken on 23 earnings calls across 1 company, most recently for ClearPoint Neuro, Inc. on October 28, 2026. ClearPoint Neuro, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at ClearPoint Neuro, Inc. includes R. John Fletcher (Chairman and Board Member), Danilo D’Alessandro (CFO), Mazin Sabra (COO) and 7 others.
“Looking at the third quarter 2026 results, total revenue was $12.1 million for the three months ended September 30th, 2026, and $8.9 million for the three months ended September 30th, 2025, which represents 36% growth versus the third quarter of 2025.”
“Looking at the second quarter 2026 results, total revenue was $10.9 million for the three months ended June 30th, 2026, and $9.2 million for the three months ended June 30th, 2025, which represents 18% growth versus the second quarter of 2025.”
“Looking at the first quarter 2026 results, total revenue was $12.1 million for the three months ended March 31st, 2026, and $8.5 million for the three months ended March 31st, 2025, which represents 43% growth versus the first quarter of 2025 and 16% organic growth.”
“Let me start by looking at the full year 2025 results. ClearPoint Neuro total revenues were $37 million for the year ended December 31, 2025, compared to $31.4 million in the year 2024.”
“Let me start by giving some further details about the proposed merger and the key transaction terms. Upon closing, ClearPoint Neuro will deliver a closing consideration of $5 million in cash and 1,325,000 shares of ClearPoint Neuro's common stock, subject to customary working capital adjustments.”
SEC 8-K
2020-09-29–present
Medical Devices · Healthcare
CFO
2020-09-29–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | ClearPoint Neuro, Inc. (CLPT) | Chief Financial Officer | $385,753 | $1,254,353 |
| 2024 | ClearPoint Neuro, Inc. (CLPT) | Chief Financial Officer | $351,816 | $1,166,367 |
| 2023 | ClearPoint Neuro, Inc. (CLPT) | Chief Financial Officer | $339,375 | $930,979 |
| 2022 | ClearPoint Neuro, Inc. (CLPT) | Chief Financial Officer | $321,207 | $918,373 |
| 2021 | ClearPoint Neuro, Inc. (CLPT) | Chief Financial Officer | $291,531 | $674,494 |
| 2020 | ClearPoint Neuro, Inc. (CLPT) | Chief Financial Officer | $70,154 | $497,317 |
